Our Pricing

Mounjaro Northern Ireland - Lowest Price UK Deal

Published on: June 03, 2026

If you're searching for mounjaro northern ireland lowest price uk options, Cured Pharmacy delivers genuine UK-licensed Mounjaro pens from £124.99 with free clinical consultation and discreet delivery across Northern Ireland. Our UK-registered prescribers assess your suitability online in under 3 minutes, and we guarantee the lowest prices in the UK market.

Why Mounjaro Northern Ireland Patients Choose Cured Pharmacy

Northern Ireland residents face the same weight management challenges as patients across the UK, yet accessing specialist weight loss treatments can involve long NHS waiting lists or unclear pricing from high-street pharmacies. At Cured Pharmacy, we've simplified the entire process: transparent upfront pricing at £135.00 a free online consultation with UK-registered prescribers, and discreet home delivery to any Northern Ireland address.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees every prescription dispensed from our GPhC-registered pharmacy (9012511), ensuring you receive genuine MHRA-licensed Mounjaro manufactured to UK standards. We've helped thousands of patients across Northern Ireland start their weight loss journey with confidence, knowing they're receiving expert pharmaceutical care at the lowest guaranteed UK price.

How Mounjaro Works for Weight Loss

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for chronic weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously, producing enhanced effects on appetite regulation, insulin secretion, and gastric emptying.

In the landmark SURMOUNT-1 trial, patients receiving the 15mg maintenance dose achieved an average body weight reduction of 22.5% over 72 weeks — significantly greater than semaglutide-based alternatives [1]. The dual-receptor mechanism means Mounjaro addresses multiple metabolic pathways involved in obesity, which may explain its superior clinical outcomes in head-to-head studies [2].

Clinical Evidence from SURMOUNT Trials

The SURMOUNT clinical trial programme enrolled over 5,000 adults with obesity or overweight plus weight-related comorbidities across multiple international sites [1]. Patients receiving tirzepatide experienced dose-dependent weight loss, with the highest dose (15mg weekly) producing average reductions exceeding 20% of baseline body weight. Importantly, 91% of participants on the 15mg dose achieved at least 5% weight loss — the threshold associated with meaningful health benefits — and 57% achieved over 20% reduction [1][3].

Mounjaro Dosing Schedule and What to Expect

Mounjaro treatment follows a gradual dose escalation protocol designed to minimise gastrointestinal side effects while optimising weight loss outcomes. Your UK prescriber will typically start you on 2.5mg once weekly for four weeks, then increase to 5mg weekly for the next four weeks. Subsequent increases to 7.5mg, 10mg, 12.5mg, and finally 15mg occur at four-week intervals, subject to tolerability and clinical response [4].

Each Mounjaro KwikPen contains four pre-filled doses, making administration straightforward. You'll inject subcutaneously into your abdomen, thigh, or upper arm on the same day each week, regardless of meals. Most patients report mild injection site reactions initially, with nausea being the most common side effect during dose escalation — these symptoms typically diminish within 2-4 weeks as your body adjusts [4].

Managing Side Effects During Treatment

Gastrointestinal symptoms including nausea, diarrhoea, and constipation affect approximately 20-30% of patients starting Mounjaro, though severity is generally mild to moderate [1]. Our clinical team recommends eating smaller, more frequent meals, avoiding high-fat foods during the initial weeks, and staying well-hydrated. If side effects persist or worsen, your prescriber may slow the dose escalation schedule or maintain you at a lower dose where you're experiencing good weight loss with minimal discomfort.

Mounjaro vs Wegovy: Comparing Weight Loss Treatments

Both Mounjaro and Wegovy are once-weekly injectable treatments licensed by the MHRA for chronic weight management, but they work through different receptor mechanisms. Wegovy contains semaglutide, a GLP-1 receptor agonist that achieved average weight loss of 14.9% over 68 weeks in the STEP-1 trial [5]. Mounjaro's dual GIP/GLP-1 action produces greater average weight loss in clinical trials, though both medications require lifelong commitment to diet and exercise modifications.

Your choice between treatments depends on several factors including your medical history, previous treatment responses, and tolerability. Some patients who experience persistent nausea on semaglutide find tirzepatide better tolerated due to its GIP activity, which may have protective effects on the gastrointestinal tract [2]. Our UK prescribers assess your individual circumstances during consultation to recommend the most appropriate option.

Who Can Use Mounjaro in Northern Ireland

Mounjaro is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea [4]. Your UK prescriber will calculate your BMI during the online consultation and review your medical history to confirm suitability.

Mounjaro is not suitable if you're pregnant, breastfeeding, or planning pregnancy, as weight loss during pregnancy carries risks to foetal development. It's also contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [4]. Patients with severe gastrointestinal disease, pancreatitis history, or diabetic retinopathy should discuss risks carefully with their prescriber before starting treatment.

Medical Assessment Requirements

Every Mounjaro prescription at Cured Pharmacy follows a thorough clinical assessment by a UK-registered prescriber. You'll complete a detailed medical questionnaire covering your weight history, previous weight loss attempts, current medications, and any relevant health conditions. Our prescribers review this information alongside your BMI calculation to ensure Mounjaro is clinically appropriate and safe for you. This assessment typically takes under 3 minutes to complete online, with prescriber review and approval usually within 24 hours on working days.

Delivery and Ongoing Support Across Northern Ireland

Once your prescription is approved, we dispatch your Mounjaro pens in 100% discreet packaging via tracked courier to any Northern Ireland address. Delivery typically takes 1-2 working days, and we provide tracking details so you know exactly when to expect your medication. All Mounjaro pens are stored in temperature-controlled conditions and dispatched with cold-chain packaging to maintain the 2-8°C storage requirement during transit.

Weight loss treatment works best with ongoing clinical support. Our team remains available by phone (+44 116 4646009) or email throughout your treatment journey to answer questions about dosing, side effects, or general concerns. When you're ready for your next supply, simply complete a brief follow-up consultation online — we'll review your progress and issue a new prescription if clinically appropriate. This streamlined process ensures you never run out of medication while maintaining the clinical oversight required for safe, effective weight management.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
3. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2023). Two-year effects of tirzepatide on glycaemic control and body weight in obesity: The SURMOUNT-1 randomised clinical trial. The Lancet Diabetes & Endocrinology, 11(9), 658–670. https://doi.org/10.1016/S2213-8587(23)00189-3 [accessed 13 August 2026]
4. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. https://www.medicines.org.uk/emc/product/14917 [accessed 13 August 2026]
5. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to diet, exercise, and medication regimens.